|
MANTLE CELL LYMPHOMA: MCL Cancer Web Page and Resources
|
|
This document describes important information gathered from the web regarding Mantle Cell Lymphoma, a type of Non-Hodgkin’s Lymphoma. This includes information about diagnosis and treatment, financial support, questions to ask your providers, abbreviations, live events, and recent presentations on MCL and Non-Hodgkins Lymphoma.
|
|
2. COVID-19 Resources for NHL Patients 4. Information About MCL Disease and Supporting Organizations 5. What Questions Should I Ask my doctor? 6. Financial and Legal Issues during MCL/Cancer Treatment 7. Upcoming Live and Virtual Events, Telephone Conferences and Webinars 8. Recent Seminars and Conference Calls 10. Treatment Options for MCL Patients 11. More Information on Specific Treatments 12. Upcoming Ideas in MCL and NHL Cancer Diagnosis and Treatments 13. MCL Patient Care Information If you have any questions or comments or would like help with our resources, please feel free to send an email to: beth@mclpage.com
|
|||||
|
|
|
|
Acor.org MCL Listserv and Mailing List |
Mantle Cell Lymphoma mailing list brought to you by the Association of Cancer Online Resources (ACOR). If you are interested in getting more information about MCL, and to communicate with other participants on the list, sign up at the link on the left. |
|
Mantle Cell Lymphoma Online Resources Patients facing an MCL diagnosis can find others to talk to, to compare experiences with, to discuss treatment strategies, to offer a virtual hug, and more. |
|
|
Facebook Mantle Cell Lymphoma Support Group This is a closed group—you will need to apply for permission to post and see contents. There are several other MCL related groups on Facebook. |
|
|
Facebook MCL Warriors This is a support group for anyone who has Mantle Cell Lymphoma, this group is for all patients, caregivers, and survivors from newly diagnosed, to in remission, to stem cell transplants patients. |
|
|
Mantle Cell Lymphoma: The Journey has been described by its own members as a loving site that truly cares about each and every person as if they were family. “We don't just talk about MCL, but about anything that has challenged MCL survivors and their caregivers, situations that they have nowhere else to talk over”. |
|
|
Facebook MCL Support Group UK This is a closed group specifically for UK MCL patients. |
|
|
Facebook MCL @ MDA Specifically for people or their caregivers with Mantle Cell Lymphoma that are being treated at MD Anderson. |
|
|
Facebook: MCL at The James Cancer Hospital at Ohio State: This group is specifically for those who have MCL and are treated at The James Cancer Hospital at Ohio State. Adlai JN is the administrator. |
|
|
Facebook: MCL Watch and Wait This is a support and information-sharing group for people who've been diagnosed with MCL and have not yet started any treatment OR who delayed treatment for at least a few months before starting treatment. If you are interested in joining this group, you must first answer all the membership questions. |
|
|
Macmillan Cancer Support UK- Online MCL Discussion Group If you're suffering from MCL, or know someone who is, join this support group. Find information including diagnosis, treatments, and drugs, as well as advice to help with the different ways cancer may impact your life. |
|
|
And Supporting Organizations
|
|
|
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma: Report of the 2023 Lymphoma Research Foundation’s Mantle Cell Lymphoma Consortium Workshop Researchers gathered at the 20th MCL Scientific Workshop held May 2-3, 2023, in Chicago, IL to discuss recent developments in both scientific and clinical research. The following report includes technical information on MCL genetics, mechanisms of resistance or response to treatment, personalization of therapy and prognostics using bioMRDs, and an international overview of clinical trials.
MCL 2023 Scientific Workshop Report Published Fall 2023 |
|
|
Annual Clinical Updates in Hematological Malignancies: Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
MCL 2022 Update from MD Anderson A comprehensive overview of MCL disease and treatment published by MD Anderson Cancer Center, Houston, TX. |
|
|
Supporting Organizations: |
|
|
|
Leukemia and Lymphoma Society (LLS): Download or order free information booklets |
|
|
Lymphoma Research Foundation (LRF): LRF Mantle Cell Lymphoma Fact Sheet
LRF Relapsed/Refractory Mantle Cell Lymphoma Fact Sheet The LRF Clinical Trials Information Service provides patients with information about investigative treatments for lymphoma being evaluated at cancer centers nationwide: |
|
The Lymphoma Support Network (LSN) is a one-to-one peer support program for people with lymphoma and their caregivers. LSN connects patients and caregivers with volunteers who have had similar experiences. More than 6,000 lymphoma survivors and their caregivers have joined LSN to connect with others, share their personal histories as they relate to lymphoma and offer emotional support. |
|
|
Lymphoma Coalition Lymphoma Coalition, a worldwide network of patient groups with a focus on providing support to patients with lymphoma, was formed in 2002 to establish a central hub of consistent, reliable, and current information. LC recognizes the need for lymphoma patient organizations to share resources, best practices, and policies and procedures. Today, there are over 80 member organizations from over 50 countries. |
|
|
The Leukemia & Lymphoma Society of Canada (LLSC) is a voluntary health agency dedicated to blood cancers. They provide free information and support services to patients and caregivers. The LLSC mission: Cure leukemia, lymphoma, Hodgkin's disease, and myeloma, and improve the quality of life of patients and their families. Click here for the French language version |
|
|
Lymphoma Action UK UK based Lymphoma information and services: |
|
|
LYSA A French based Lymphoma information and services resource. Available in both French and English. (Click on flag at top right for language preference). |
|
|
National Comprehensive Cancer Network NCCN is a not-for-profit alliance of 31 leading cancer centers devoted to patient care, research, and education. Clinical professionals at NCCN Member Institutions develop resources that present valuable information to the numerous stakeholders in the health care delivery system. NCCN promotes and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world. |
|
|
Patient Power Patient Power is devoted to supporting cancer patients, care partners and other loved ones through education and advocacy - to get the right treatment at the right time working with the right healthcare team. Patient Power offers an ever-expanding library of online programs, organized by health condition. |
|
|
Patients Against Lymphoma The Lymphomation website has general lymphoma information, including a list of lymphoma related acronyms |
|
|
Lymphoma Hub.com The Lymphoma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. |
|
|
LymphomaInfo.net Lymphoma news, support, and information. |
|
|
PubMed A free search engine accessing the MEDLINE database of references and abstracts on life sciences and biomedical topics. Search the database for scholarly publications on MCL disease and treatment. Maintained by NCBI. |
|
|
NCI Adult NHL Treatment NIH sponsored general information and treatment options guide with a version for patients and healthcare providers. |
|
|
Navigating Care Support, resources, and tools to manage patients’ cancer care. Patients can organize care and manage health records in one place. |
|
|
BMT InfoNet A valuable resource dedicated to providing transplant patients, survivors and caregivers high quality information on blood and marrow transplants and related issues. |
|
|
BMT Infonet en Espańol Una colección de videos sobre trasplantes y terapia CAR T en espańol. |
|
|
BeTheMatch.org Helping patients by providing one-on-one support to them and their families every step of the way along the transplant journey. |
|
|
NCI Office of Cancer Survivorship The office works to enhance the quality and length of survival of all persons diagnosed with cancer and to minimize adverse effects experienced during cancer survivorship. The office supports research that addresses the physical, psychological, social, and economic effects of cancer and its treatment. |
|
|
Cancer.net site from ASCO & Conquer Cancer Foundation main web site |
Cancer.Org Devoted to information about all cancers. From the website developed by the American Society of Clinical Oncology: |
|
Cancercare.org Provides counseling, support groups, education, publications, financial assistance, and community programs. |
|
|
Cancercare social workers are experienced in the mental health aspects of cancer and provide free counseling services. Phone number 800‑813‑HOPE (4673) (select option 5 for counseling services); or email info@cancercare.org |
|
|
Cancer.gov A US Government search engine for clinical trial information from the National Cancer Institute. |
|
|
OncLive News Network Covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions with videos presented by experts specific to MCL disease. These articles are primarily designed for physicians but can provide some useful ideas about treatment possibilities. |
|
|
What Questions Should I Ask my Doctor?
|
|
|
American Cancer Society General Questions
|
American Cancer Society general questions for all cancers. |
|
American Cancer Society questions on Non-Hodgkin’s lymphoma. |
|
|
Second Opinions: You might want to find another doctor who can look at your test results, talk with you about your personal situation, and maybe give you a different take on it. Getting a second opinion can help you feel more sure about your diagnosis and treatment plan. |
|
|
Talking Through Treatment for the Best Care: |
|
|
This LLS podcast provides information on how both healthcare professionals and patients can improve their communication as they discuss diagnosis and treatment. |
|
|
Financial and Legal Issues During MCL/Cancer Treatment
|
|
|
US Government website link explaining the expedited process for people diagnosed with MCL to automatically qualify for federal Social Security Disability benefits. See more about Compassionate Allowances (Note: The MCL survival statistics in this website are out of date.) |
|
|
You Aren’t Alone: Navigating The Financial Impact of Cancer Monica Bryant, Esq., a cancer rights attorney and Co-founder/Chief Operating Officer of Triage Cancer reviews the financial hurdles that may arise during treatment and provides practical strategies to help with economic hardships. She also highlights a wealth of resources designed to aid patients, covering everything from financial grants to transportation, Social Security benefits and navigating the complex world of health insurance. Recorded April 10, 2024 |
|
|
This booklet published by LLS describes health insurance options and resources to help patients and their families who are coping with the financial aspects of cancer care, including worksheets to help you stay organized. |
|
|
Empowers and educates people with cancer to thrive in their workplace by providing expert advice, interactive tools, and educational events. |
|
|
Provides invaluable cancer-related legal information and resources to people nationwide. Their Telephone Assistance Line hosts conferences, seminars, workshops, education and outreach programs, and other cancer community activities. |
|
|
The Leukemia & Lymphoma Society's (LLS) Susan Lang Pre CAR-T-cell Therapy Travel Assistance program is available to blood cancer patients with significant financial need. The fund provides financial assistance to patients diagnosed with a blood cancer who are being evaluated to receive CAR T-cell therapy as either standard treatment or a clinical trial. Those who qualify will receive $2,500 in financial assistance to support approved travel and lodging expenses. |
|
|
Health and financial resources including state laws related to employment, disability, and health insurance. International resources list cover cancer research, disability benefits, legal assistance, and employment health insurance in Australia, Canada, and England. |
|
|
Conquer Magazine’s patient guide is a comprehensive list of organizations offering services related to obtaining financial support and cancer care management. |
|
|
Helpful site with support services for cancer patients, especially financial and counseling. |
|
|
Giving Home Health Care helps qualifying blood cancer patients who have worked at a Department of Energy (DOE) facility. Giving Home Health Care is an organization that helps individuals, who were employed with the DOE, receive financial assistance and other services they are legally entitled to under the Energy Employees Occupational Illness Program (EEOICPA). |
|
|
PAN Foundation provides support for medical expenses. |
|
|
LLS sometimes has funding for patients related expenses. A fund that is “fully subscribed” is at maximum capacity. There is no waitlist and encourage all to continue to check the website regularly for updates. |
|
|
Leukemia and Lymphoma Society Financial Support Page |
|
|
Leukemia and Lymphoma Society virtual lecture can be accessed at any time to help patients and caregivers deal with financial concerns. |
|
|
Lymphoma Research Foundation Financial Support Page LRF has compiled a list of available resources providing financial assistance. |
|
|
VETERAN DENTAL FINANCIAL ASSISTANCE Dental services provided to eligible veterans at sites in New York, NY, Chapel Hill, NC and San Antonio, TX. |
|
|
Dollar For helps you apply for financial assistance from your hospital stay. Take a 3-minute survey to see if you qualify. |
|
|
Undue Medical Debt is a national nonprofit whose purpose is to strengthen communities by erasing financially burdensome medical debt. Founded in 2014 by former debt collection executives, Undue Medical Debt is one of the leading charitable organizations that help pay medical bills. |
|
|
Singlecare.com offers insights on managing medical debt, offering strategies, resources, and practical advice to navigate healthcare finances effectively. |
|
|
NeedyMeds is a national non-profit that connects people to programs that will help them afford their medications and other healthcare costs. |
|
|
A listing of Drug Assistance Programs from pharmaceutical companies. |
|
|
The Job Accommodation Network (JAN) is the leading source of free, expert, and confidential guidance on workplace accommodations and disability employment issues. |
|
|
Upcoming Live and Virtual Events, Telephone Conferences and Webinars
|
|
|
Update on B-Cell Lymphomas from the American Society of Hematology (ASH) Annual Meeting 2024
Jan 15, 2025 2:00 PM ET/ 11:00 AM PT The Lymphoma Research Foundation's free webinars are hour-long interactive programs led by leading lymphoma experts who discuss lymphoma, treatment options, clinical trials, and promising innovative research. Webinars can be listened to live on the telephone or via web streaming. This program will cover updates in B-Cell lymphoma research for lymphoma patients and their care partners. Presenter: Ann LaCasce, MD, MMSc |
|
|
Northern California Blood Cancer Conference - REGISTRATION IS NOW
OPEN! SAVE THE DATE Winter/Spring 2025
Rocky Mountain Blood Cancer Conference
Southern California Blood Cancer Conference
Tri-State Blood Cancer Conference
Texas Blood Cancer Conference |
|
|
|
Ask the Doctor About Lymphoma: Ask the Doctor is a national series of two-hour, topic-specific, community-based programs that combine a presentation by a medical doctor with an extensive question and answer session. Virtual Ask the Doctor programs provide access to local lymphoma experts, and you can tune in over the phone or online. Note: Ask the Doctor programs are not recorded or archived. We encourage you to tune in live. Click on the links for more information and registration:
Information for Newly Diagnosed Patients Featuring: Dr. Ryan Lynch, Fred Hutchison Cancer Center January 28, 2025 4:00 PM – 6:00 PM ET/ 1:00-3:00 PT This program is for individuals who have been recently diagnosed with lymphoma/CLL or have received one line of treatment.
|
|
Balancing Work & Cancer: Webinars/ Teleconferences Cancer and Careers’ Balancing Work & Cancer Webinar Series offers sessions related to the challenges of balancing work and cancer. Click on the links for more information and to register for the sessions:
Balancing Work & Cancer: Making Key Decisions Webinar/Teleconference Learn how to figure out the steps and considerations when making decisions about work when managing a diagnosis.
FEB 5, 2025 Balancing Work & Cancer Webinar: Managing Long-Term Stress Webinar/Teleconference Discover ways to care for yourself and create new strategies to manage stress and maintain a professional presence in the workplace.
MAR 5, 2025 Balancing Work & Cancer Webinar: Building Confidence at Work Webinar/Teleconference Explore the impact of cancer upon body confidence and self-confidence and how those changes can affect patients and survivors in the workplace.
MAR 28, 2025 12th Annual Midwest Conference on Work & Cancer Webinar/Teleconference This free daylong event explores the complexities of balancing treatment and recovery with employment.
APR 2, 2025 Balancing Work & Cancer Webinar: Marketing Yourself: Job Search and Beyond Webinar/Teleconference Knowing how to sell yourself is a key skill when applying for jobs, writing a cover letter, and in an interview. You know why you are perfect for the MAY 6, 2025 Balancing Work & Cancer Webinar: Job Search Tools: Using AI Strategically Webinar/Teleconference This session will take a practical look at using AI in your job search by explaining what AI is, and isn’t, and demonstrating how to use it.
JUN 4, 2025 Balancing Work & Cancer Webinar: First Impressions: Resumes and LinkedIn Webinar/Teleconference Learn all the resume basics to ensure it tells a compelling story of your professional experiences and accomplishments.
JUL 9, 2025 Balancing Work & Cancer Webinar: Career Shifting: Tips, Tools & Techniques Webinar/Teleconference Explore the challenges of seeking a change in your career following a cancer diagnosis or treatment, and methods to overcome them.
AUG 6, 2025 Balancing Work & Cancer: Balancing Work & Cancer Webinar/Teleconference Learn ways to manage work after a cancer diagnosis
SEP 10, 2025 Balancing Work & Cancer Webinar: Communicating Effectively Part 1 Webinar/Teleconference Explore tools and techniques for communicating effectively in the workplace after a cancer diagnosis and treatment.
OCT 8, 2025 Balancing Work & Cancer Webinar: Communicating Effectively Part 2 Webinar/Teleconference Explore tools and techniques for communicating effectively in the workplace after a cancer diagnosis and treatment.
NOV 5, 2025 Balancing Work & Cancer Webinar: Balancing Work & Caregiving Webinar/Teleconference There are unique challenges in balancing caregiving responsibilities and work. This webinar will touch on considerations to make it manageable.
DEC 3, 2025 Balancing Work & Cancer Webinar: Self-Care: Practical Approaches at Work and Beyond Webinar/Teleconference Between doctor appointments, treatment schedule and work, we often neglect to take time for ourselves.
|
|
|
|
|
|
Link |
Description |
|
ACOR MCL Zoom Meeting Series Recordings of monthly discussions hosted by ACOR MCL
Q and A with Dr Tycel Phillips Presented by Tycel Phillips, MD, Associate Professor of Hematology and Bone Marrow Transplant at City of Hope, Duarte, CA Recorded July 1, 2024
Searching Online for MCL Medical Information Presented by Daniel Schneider and Larry Fagan Recorded June 1, 2024
MCL Webpage Resources and Finding Clinical Trials Presented by Beth Parle and Larry Fagan Recorded April 6, 2024
High Risk MCL and Watch and Wait Presented by Tycel Phillips, MD, Associate Professor of Hematology and Bone Marrow Transplant at City of Hope, Duarte, CA Recorded March 2, 2024 |
|
|
Spotlight on Mantle Cell Lymphoma Topics Covered: · Latest treatment advances for mantle cell lymphoma · Relapse management · Quality-of-life and side-effect management Presented by Tycel Philips, MD, City of Hope National Cancer Center, Duarte, CA Recorded March 1, 2024 |
|
|
Presentations from the National Virtual Blood Cancer
Conference Lymphoma
High Grade Transforming
Cancer Care with Integrative Oncology |
|
|
Update on Lymphoma from the 2023 American Society of Hematology (ASH) Annual Meeting Program Overview
Featuring: John P. Leonard, MD, New York Presbyterian Hospital, Weill Cornell Medicine, LRF Scientific Advisory Board Member Jamie E. Flerlage, MD, MS, Golisano Children’s Hospital Neha Mehta-Shah, MD, MSCI Recorded January 29, 2024 |
|
|
Mantle Cell Lymphoma Presented by Brad Kahl, MD Washington University, Siteman Cancer Center, St Louis, MO This comprehensive one-hour presentation from the National Lymphoma Workshop is an in-depth dive about all aspects of MCL. Recorded November 4, 2023
Dr. Brad Kahl - MCL treatment & survivorship In addition, a patient Q and A session was recorded on December 1, 2023 To view that content Please click here Enter Passcode: Yn9*VR3w |
|
|
Treating Lymphoma with Bispecific Antibodies This one-hour video is an in-depth overview of how bispecific antibodies are being used to attack lymphoma using a two-pronged approach to recognize the targets expressed on the cell surface called anitgens. Glofitamab (COLUMVI), Odronextamab (ODRON) and Epcoritamab (Epkinly) are currently being studied in clinical trials to treat mantle cell lymphoma. Presented by: Lorenzo Falchi, Memorial Sloan Kettering, New York, NY and Jennifer Crombie, MD, Dana Farber Cancer Institute, Boston, MA Recorded July 19, 2023 |
|
|
Resilience Through Progress: Slow Growing Non-Hodgkin Lymphoma (NHL) Topics Covered · How your NHL subtype determines treatment goals and strategies · Navigating the uncertainty of a chronic disease · New therapies on the horizon · Methods to manage side effects Speaker J.C. Villasboas B., MD Recorded December 1, 2023 |
|
|
Update on CAR T-Cell Therapy Webinar This one-hour video is an in-depth overview of the history of lymphoma treatment from chemotherapy to immunotherapy with a detailed summary of best practices in CAR T therapy. Presented by Manali Kamdar, MD, University of Colorado Recorded August 16, 2023 |
|
|
Updates in Treatment and Management of B-Cell Malignancies André Goy, MD, and Andrew Ip, MD, discuss clinical trial data and the evolving treatment landscapes for mantle cell lymphoma and diffuse large B-cell lymphoma. Episodes 1 through 5 are MCL specific. Recorded April-May 2023 |
|
|
Update on Relapsed/Refractory Mantle Cell Lymphoma This one-hour presentation by Alexy Danilov, MD, of City of Hope is an in-depth summary of available treatment options for relapsed/refractory patients. Recorded March 23, 2023 |
|
|
In Discussion: Mantle Cell Lymphoma Podcast Series: Episode 1: Autologous Stem Cell Transplant for MCL and the Transition Toward the Use of BTK Inhibitors
Episode 2: Unpacking the Addition of New Variables to the MCL International Prognostic Index and MRD Episode 3: The Past, Present and Future of Bendamustine in MCL Episode 4: CAR T and Immunotherapy in MCL: Bridging Therapy, Toxicities, and Bispecific Antibodies Episode 5: Pathology of Mantle Cell Lymphoma: Biopsies, Diagnostic Markers, and Options for Clinicians Treating This Disease Episode 6: Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: Mutations and Mechanisms of Resistance
Presented by Peter Martin, MD, Weill Cornell Medical College Recorded March, 2023 |
|
|
Recent Advances in the Treatment of Mantle Cell Lymphoma In these 13 episodes, a panel of experts in hematologic malignancies have an engaging discussion on the current and potential future treatment approaches for MCL. Alexey V. Danilov, MD, PhD; City of Hope,
Duarte, CA Recorded January-February 2023 |
|
|
Martin Dreyling, MD, Talks TRIANGLE Trial, MCL Management During this 46-minute video, Dr. Dreyling, Associate Professor of Medicine at the University of Munich, leads listeners through the management of mantle cell lymphoma in newly diagnosed patients. He also answers questions on treating patients without access to upfront ibrutinib access as per the TRIANGLE trial, if allogeneic transplant has a role in MCL, and more. Recorded May 3, 2023 |
|
|
Mantle Cell Lymphoma Research and Clinical Trials John P Leonard, MD of Weill Cornell Medicine discusses recent advances in MCL treatments such as BTK inhibitors, CAR-T, bispecific antibodies, antibody drug conjugates and other agents available through clinical trials. Recorded March 2023 |
|
|
What’s New in Diagnostic Technologies for People Living with Blood Cancers CancerCare Workshops are intended for patients and caregivers. Presented by: Peter Martin, MD, Weill Cornell Medicine, NY Presbyterian Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center Ruben A. Mesa, MD, FACP, MD Anderson, Mays Cancer Center Elizabeth K. O’Donnell, MD, Massachusetts General Hospital Joseph Khoury, MD, FCAP, MD, M. D. Anderson Cancer Center Sarah Thibault-Sennett, PhD, Association for Molecular Pathology (AMP) Recorded January 31, 2022 |
|
|
Master Listings of MCL and Cancer Talks: |
|
|
DECISION POINT: Medscape Hematology & Oncology This interactive tool enables users to filter their searches to find a variety of MCL videos on diagnosis, evaluation, management, treatment, emerging therapies and care. |
|
|
Listings of past webcasts from the Leukemia and Lymphoma Society. These educational programs cover topics related to lymphoma and its subtypes. Click on the links to access webcasts, audio replays, transcripts, and program slides |
|
|
The Bloodline with LLS Listen in as experts and patients guide listeners in understanding diagnosis, treatment, and resources available to blood cancer patients. Join The Patient Education Team at The Leukemia & Lymphoma Society as they explore various survivorship topics. |
|
|
CancerCare A listing of past presentations from Cancercare.org. |
|
|
Finding MCL Treatment: Cancer Centers and Physician Information
|
|
|
|
|
|
National Cancer Institute- Designated comprehensive cancer centers
|
|
|
US News & World Report: Best Hospitals for Leukemia, Lymphoma & Myeloma
|
https://health.usnews.com/best-hospitals/hospital-ratings/leukemia-lymphoma-myeloma
|
|
US News & World Report: Best Hospitals for Cancer
|
|
|
A guide to choosing doctors and finding treatment:
|
|
|
LLS Information Booklet |
Choosing a Specialist or Treatment Center This guide offers suggestions on selecting your doctor, healthcare team and treatment center. |
|
Findexpertmd.com This database gathered information on 1,207 top medical experts on Mantle-Cell Lymphoma across 40 countries and 40 U.S. states, including 1,180 physicians. This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.
|
Find Expert Doctors on Mantle Cell Lymphoma*
* findexpertmd.com, calculates a ranking of specialty doctors using their own proprietary algorithm. Many of the doctors mentioned are very active in MCL research. Please use additional information and your own research to select a provider to see. ACOR and the MCL community are not responsible for the use of this list. |
|
The American Cancer Society’s online aid to finding the right treatment team.
|
|
|
Doctors with an interest in treating MCL: Disclaimer: The following physicians have been mentioned in our MCL/ACOR mailing list or have been involved in instructional presentations related to MCL. Providers are presented alphabetically by US state and no rank ordering is implied. No endorsement by ACOR or members of the MCL mailing list is implied by this information. This list is presented solely as a possible starting point for the many patients that are seeking additional opinions about their medical care. |
|
|
Treatment Options for MCL Patients
|
||
|
Researching Treatment Options: |
Link |
Description |
|
ClinicalTrials.gov |
A US Government registry of clinical trials maintained by the NIH. It is the largest database of trials with currently over 230,000 trials from 195 countries. You can search for MCL clinical trials while filtering results by location, stage, and eligibility. |
|
|
LLS Clinical Trial Nurse Navigators |
Work one-on-one with an LLS Clinical Trial Nurse Navigator who will personally assist you throughout the entire clinical-trial process. Clinical Trial Nurse Navigators are registered nurses with expertise in blood cancers. |
|
|
LLS Treatment Booklet |
The booklet is written in both English and Spanish.Topics covered- · Treatments for Blood Cancer · Ask Your Healthcare Provider to Explain Your Treatment Options · What Is a Clinical Trial? · Are Clinical Trials Safe? · Informed Consent · Clinical Trials: An Important Option for Everyone · How to Talk to Your Healthcare Providers · Questions to Ask Your Healthcare Providers About Treatment Options · Clinical Trials Support |
|
|
American Cancer Society |
An overview of the types and phases of clinical trials and what they mean to pateints. |
|
|
Cancer.gov |
National Cancer Institute overview of Non-Hodgkin’s Lymphoma diagnosis and treatment. |
|
|
FDA.gov |
FDA information on gaining access to unapproved drugs. |
|
|
Treatment Stage |
Link |
Description |
|
All Stages of Treatment
|
OncLive.com First Line Treatment
OncLive.com Second Line Treatment
|
Current Treatment Options in MCL Experts on mantle cell lymphoma discuss first-line, second-line and third-line treatment options available for patients. While intended for oncologists, MCL patients may find these videos informative.
Recorded January-Februay 2024 |
|
All Stages of Treatment
|
Maddocks Shares Updates on Emerging Treatment Strategies in MCL Efforts to widen the treatment armamentarium for patients with mantle cell lymphoma have been thwarted by increased toxicities and resistance mechanisms with effective therapies such as BTK inhibitors.Published online September 12, 2023 |
|
|
All Stages of Treatment
|
Current Treatments in Mantle Cell Lymphoma A comprehensive overview of MCL with up-to-date information on treatments and risk stratification. Avyakta Kallam, MD, City of Hope Julie Vose MD, University of Nebraska Medical Center Published August 16, 2023 |
|
|
All Stages of Treatment
|
MCL Treatment Algorithm from MD Anderson, Houston, TexasUpdated May 21, 2024 |
|
|
Frontline Treatment |
ASH 2023 Updates on Frontline Therapies in MCL In this 7 minute video, a panel of MCL experts discuss advances in the front-line setting. Published February 6, 2024 |
|
|
Frontline Treatment for Older Patients |
First-Line Treatment for Older Patients With Mantle Cell Lymphoma: Venetoclax Plus Standard Chemoimmunotherapy The phase II PrE0405 achieved a complete response rate of 85% in 33 patients with MCL over age 60 who received bendamustine and rituximab along with venetoclax. The combination was generally well tolerated, according to Craig A. Portell, MD, who presented the data at the 2023 ASH Annual Meeting & Exposition (Abstract 733). Posted online December 18, 2023 |
|
|
Frontline Treatment |
Wang Details Caveats to Standards of Care for Treating Patients With MCL Michael Wang, MD of MD Anderson discusses early identification and appropriate frontline therapy. Therapies may vary for those 65 years and older compared with patients under the age of 65, with several additional factors also having a role in approaching treatment options for a new patient in the clinic. Published February 23, 2023 |
|
|
Central Nervous System Involvement |
Mantle Cell Lymphoma and Central Nervous System InvolvementIn this 7-minute video, Peter Martin, MD, at Weill Cornell discusses the approaches taken for treating patients that show CNS involvement.Published March 18, 2022 |
|
|
Central Nervous System Involvement |
Complete response of MCL with CNS involvement at diagnosis with acalabrutinibThis case report describes the first patient to have a complete response with front-line treatment with single agent acalabrutinib for MCL CNS.Published December 26, 2023 |
|
|
Relapsed/Refractory |
Evolving Treatment Patterns Lead to Improved Outcomes in Relapsed/Refractory MCLPatients with R/R MCL have experienced event-free survival and overall survival benefits due to advances in second-line treatment approaches over time.Published November 20, 2023 |
|
|
Relapsed/Refractory |
Evaluating Effective Treatment Options and Strategies for Relapsed/Refractory Mantle Cell LymphomaTycel Phillips, MD, City of Hope National Medical Center in Durate, California discussed different strategies that can be effective as second-line treatments in various patients who have relapsed/refractory mantle cell lymphoma.Published October 15, 2022 |
|
|
Indolent MCL |
Indolent MCL |
|
|
More Information on Specific Treatments
|
||
|
Bispecific Antibodies: |
||
|
Bispecific Antibodies |
Understanding Lymphoma and Bispecific Antibodies Bispecific antibodies (bsAbs) are an innovative class of immunotherapy drugs designed to recognize two different targets expressed on the cell surface, called antigens. |
|
|
Bispecific Antibodies |
Bispecific Antibody Therapy for Lymphoma: What You Need to Know Bispecific antibodies are designed to recognize and bind to more than one cell marker. These therapies provide a valuable new option for patients. Published March 14, 2024 |
|
|
Bispecific Antibodies |
The Role of Bispecific Antibodies in Mantle Cell Lymphoma A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma. Presented by Alexy V. Danilov, MD and Bijal D. Shah, MD Published February 21, 2023 |
|
|
Glofitimab (Columvi)
|
City of Hope’s Dr Tycel Phillips Discusses Promise of Glofitamab in Heavily Pretreated MCL An updated analysis from a phase I/II study show that most patients with heavily pretreated relapsed/refractory MCL with a complete response at the end of therapy were alive and progression free at 15 months after therapy ended. Recorded June 1, 2024 |
|
|
Glofitimab (Columvi) |
Columvi Shows High Response Rates and Safety in R/R Mantle Cell Lymphoma After a median follow-up of 19.6 months, the complete response (CR) rate was 78.3% and the overall response rate (ORR) was 85%. Published November 19, 2024 |
|
|
Glofitimab( Columvi) |
Glofitamab Yields High Responses in Small R/R Mantle Cell Lymphoma Cohort Complete responses in patients with pretreated relapsed/refractory mantle cell lymphoma treated with glofitamab appear to be early and enduring. Published online October 9, 2023 |
|
|
BCL-2 inhibitor |
||
|
Venetoclax (Venclexta)
|
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma Published June 28, 2023 |
|
|
Venetoclax (Venclexta) |
Venetoclax Plus Lenalidomide -Rituximab Elicits High Response Rates in Newly Diagnosed MCL Published online July 22, 2021 |
|
|
BTK Inhibitors: |
||
|
Pirtobrutinib (LOXO-305) |
FDA Approves Pirtobrutinib (Jaypirca) for Relapsed or Refractory Mantle Cell LymphomaOn January 27, 2023, the Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib (Jaypirca) for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. |
|
|
Pirtobrutinib
|
ASH 2023: Jonathon B. Cohen, MD, on Mantle Cell Lymphoma: New Data on Pirtobrutinib Jonathon B. Cohen, MD, of Winship Cancer Institute, Emory University, discusses safety and efficacy findings from the phase I/II BRUIN study. The trial found that pirtobrutinib continues to demonstrate durable efficacy and a favorable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma (Abstract 981). Recorded December, 2023 |
|
|
Pirtobrutinib |
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma A report of the safety and efficacy of pirtobrutinib in patients with pretreated MCL. Published August 20, 2023 |
|
|
Pirtobrutinib |
Pirtobrutinib Yields Sustained Efficacy in R/R Mantle Cell Lymphoma The non-covalent BTK inhibitor shows an encouraging duration of response in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma, according to data. Published June 12, 2023 |
|
|
Orelabrutinib (ICP-022) |
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm studyORR was 81.1%, with 27.4% achieving complete response and 53.8% achieving partial response.Published April 20, 2023 |
|
|
Orelabrutinib
|
Orelabrutinib Effective for the Treatment of R/R MCLNew research from China indicates that the irreversible BTK inhibitor orelabrutinib is an effective treatment for patients with R/R MCL and has an acceptable side effect profile.Published December, 2023 |
|
|
Ibrutinib |
Dr Habermann on Data Leading to the Withdrawal of Ibrutinib in MCLIn this video, Thomas M. Habermann, MD, discusses the data that led to the decision to withdraw the indication for ibrutinib for the treatment of patients with mantle cell lymphoma. Published May 16, 2023 |
|
|
Ibrutinib |
Ibrutinib Withdrawn from Market by Developer for MCL and MZL IndicationsMixed study results for ibrutinib have led the developer to voluntarily withdraw the agent from the United States market for the treatment of mantle cell and marginal zone lymphoma subgroups.Published Apr 10, 2023 |
|
|
Ibrutinib |
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory MCL:A Pooled Analysis of 3 Clinical Trials with Nearly 10 Years of Follow-upA multi-center retrospective study. Published May 2022. |
|
|
Acalabrutinib (Calquence) |
Acalabrutinib Demonstrates Long-Term Activity in Relapsed/Refractory MCLAcalabrutinib monotherapy continued to be highly active and safe in patients with relapsed/refractory mantle cell lymphoma with longer-term follow-up.Published August 14, 2021 |
|
|
Zanubrutinib (Brukinsa) |
Zanubrutinib Associated With Longer Treatment Persistence, Duration, and TTD in Real-World MCLMCL patients treated with ibrutinib (Imbruvica), acalabrutinib (Calquence), or zanubrutinib (Brukinsa) showed that those treated with zanubrutinib experienced longer treatment persistence, treatment duration, time to discontinuation (TTD), and lower switching rates compared with acalabrutinib and ibrutinib.Published April 17, 2024 |
|
|
Zanubrutinib (Brukinsa) |
Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive ReviewZanubrutinib (BGB-3111) is the newest BTK inhibitor used for the treatment of MCL. It was approved by the FDA on November 14, 2019, for adult patients with MCL who have received at least one prior therapy.Published November 24, 2023 |
|
|
CAR T: |
||
|
CAR-T |
|
This fact sheet provides information about chimeric antigen receptor (CAR) T-cell therapy, which is a type of immunotherapy. |
|
CAR-T Breyanzi lisocabtagene maraleucel |
FDA Approves CAR T Cell Treatment for Resistant Mantle Cell Lymphoma On May 30, 2024, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi). |
|
|
CAR T brexucabtagene autoleucel (brexu-cel; Tecartus) |
Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma Five-year follow-up data from cohorts 1 and 2 of the phase 1/2 ZUMA-2 trial (NCT02601313) showed that treatment with the CAR T-cell therapy brexucabtagene autoleucel (brexu-cel; Tecartus) led to durable responses and high overall survival (OS) rates in patients with relapsed/refractory MCL. Published December 18, 2024 |
|
|
CAR-T |
Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma Key Takeaways · CAR T-cell therapy in MCL shows high efficacy with an ORR of 89% and CR rate of 74%. · Safety concerns include 86% incidence of any-grade CRS and 52% of any-grade ICANS. · Subgroup analyses highlight response variability based on Ki-67 index, TP53 mutations, and prior treatments. · Brexucabtagene autoleucel and lisocabtagene maraleucel are FDA-approved for relapsed/refractory MCL. · Future research should focus on long-term efficacy and optimizing treatment strategies. Published Ocotvber 14, 2024 |
|
|
CAR-T Tecartus (brexucabtagene autoleucel, also known as brexu-cel), |
‘Remarkable’ Results from Tecartus in Patients With R/R MCL Patients with relapsed/refractory MCL described as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus (brexucabtagene autoleucel, also known as brexu-cel), according to recent study findings. Published January 4, 2024 |
|
|
CAR-T |
Does BTKi improve CAR T-cell therapy in MCL? The phase 1/2 TARMAC study establishes the use of ibrutinib, starting before apheresis, with CAR T cells to be both safe and feasible in patients with MCL. Correlative analyses presented successfully lay the foundation to determine whether BTKi inhibition augments CD19 CAR T-cell activity in patients with MCL and other lymphomas. Published February 22, 2024 |
|
|
CAR-T |
Liso-cel Effective in Patients with Relapsed or Refractory MCL with High-risk Disease Features Lisocabtagene maraleucel (liso-cel) demonstrated clinically meaningful efficacy across subgroups of patients with relapsed or refractory MCL with high-risk disease features such as high proliferation index (Ki-67 ≥30%), TP53 mutation, blastoid morphology, and secondary central nervous system (CNS) lymphoma, according to a recent study. Published December 6, 2023 |
|
|
CAR-T |
Lisocabtagene Maraleucel Induces Significant Response in FL and MCL Populations Treatment with lisocabtagene maraleucel (liso-cel; Breyanzi) led to statistically significant and clinically meaningful responses in the phase 2 TRANSCEND FL study (NCT04245839) of the agent in patients with relapsed/refractory follicular lymphoma (FL), and in the phase 1 TRANSCEND NHL 001 study (NCT02631044) of patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including mantle cell lymphoma. Published May 2, 2023 |
|
|
CAR-T |
CAR T cell Immunotherapies: FDA Safety Communication - FDA Investigating Serious Risk of T-cell Malignancy The FDA warns that T-cell malignancies have occurred in patients treated with several products in the class. The products include:
Posted online November 28, 2023 |
|
|
CAR-T |
Oncologists Defend CAR-T After FDA Advisory The FDA announced that BCMA- or CD19-directed autologous CAR T cell therapies were under review after the agency received reports of several secondary blood cancers in patients who have been treated with them. But leading oncologists say the cancers appear to be rare and the therapy is lifesaving in the context of deadly malignancies that have already outwitted chemotherapy and radiation. Published December 18, 2023 |
|
|
CAR-T |
CAR T-Cell Therapy: What to Expect Before, During and After If you are considering CAR T-Cell Therapy. This free easy-to-read colorful booklet will help you understand what to expect when going through treatment. |
|
|
CAR-T |
Quality of Life after CAR T-cell Therapy Most patients who receive CAR T-cell therapy report a good quality of life long-term. In this 40 minute videso, learn how CAR T-cell therapy is performed and its short-term and long-term effects on patients and caregivers. Discover key differences between CAR T-cell, stem cell transplant and other and chemotherapy treatments. Recorded April 30, 2024 |
|
|
CAR-T with Radiation |
Optimizing CAR T cell therapy with bridging radiation therapy The more tumor cells that are eliminated with radiation therapy before CAR T cell therapy, the less work the CAR T cells have to do. Published September 29, 2023 |
|
|
HT Scoring
|
HT Scoring Identifies Risk and Outcomes of CAR T Therapy for MCL Analyses show that a hematoxicity scoring system could identify poor treatment outcomes for patients with MCL treated with brexucabtagene autoleucel (brexu-cel; Tecartus) CAR T-cell therapy. Published October 29, 2023 |
|
|
Allogenic CAR-T |
ALLO-501– and ALLO-647–Based Lymphodepletion Well Tolerated in Advanced Non-Hodgkin Lymphoma Sattva Neelapu, MD, MD Anderson, discusses the potential of donor CAR-T cell therapy. |
|
|
Cytokine Release Syndrome (CRS) |
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures This review sheds light on the potential immunotherapeutic approaches that can be used to overcome CRS associated with T cell activation. Published May 25, 2023 |
|
|
Chemotherapy: |
||
|
R-CHOP
Hyper-CVAD
VcR-CAP
|
Combination Chemotherapy for Mantle Cell Lymphoma Doctors use several chemotherapy combinations to treat MCL, named for the first letter of each drug. Here is an overview of the drugs used in these therapies. Updated February 24, 2023 |
|
|
Combination Therapies: |
||
|
Acalabrutinib (Calquence) and Zanubrutinib (Brukinsa) |
BTK Inhibitor–Associated AEs Can Influence Treatment Selection in MCLA discussion of the current roles of acalabrutinib and zanubrutinib in MCL management, how the AE profiles of each agent influence treatment decisions, and ongoing research efforts that aim to determine the feasibility of leveraging BTK inhibitors in combination regimens for specific patient subsets. |
|
|
Acalabrutinib and Rituximab |
Regimen Produces High Response Rate in Newly Diagnosed MCLAcalabrutinib and rituximab (AR) given before and after chemoimmunotherapy and transplant appears safe and active in patients with mantle cell lymphoma (MCL), according to research presented at the ASH Annual Meeting 2023.Published online December 12, 2023 |
|
|
Acalabrutinib +Bendamustine +Rituximab |
Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell LymphomaThe addition of Acalabrutinib to bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in PFS.Published June 17, 2024 |
|
|
Acalabrutinib +Bendamustine +Rituximab |
Discussing The Role of Acalabrutinib in Triplet Therapy for MCL Tycel Phillips, MD discusses the addition of the BTK inhibitor acalabrutinib to the combination of bendamustine and rituximab proved to be tolerable and effective enough to warrant expansion to a phase 3 trial for patients with either treatment-naive or relapsed/refractory mantle cell lymphoma. Published July 18, 2023 |
|
|
Acalabrutinib +Venetoclax +Obinutuzumab |
Acalabrutinib Triplet Shows Early Signals of Activity, Safety in R/R Mantle Cell Lymphoma The combination regimen comprised of acalabrutinib, venetoclax, and obinutuzumab proved to be safe and feasible and to elicit responses in patients with high-risk, relapsed or refractory mantle cell lymphoma. Published December 19, 2023 |
|
|
Ibrutinib plus Venetoclax
|
Ready, AIM, stop: ibrutinib plus venetoclax in MCL A 7-year follow-up of the AIM trial assessing the combination of ibrutinib and venetoclax in patients with MCL, most of whom had relapsed or had refractory disease. In this updated report, they highlight the long-term benefit and the results of a protocol amendment allowing patients in confirmed measurable residual disease (MRD)-negative complete remissions to stop therapy after a 1-year minimum of combination treatment. |
|
|
CAR T CTL019 Plus Ibrutinib
|
CTL019 Plus Ibrutinib is Feasible and Effective in Relapsed/Refractory MCL Treatment with CTL019 CAR T cells, the investigational form of tisagenlecleucel (Kymriah), in combination with time-limited ibrutinib (Imbruvica) demonstrated efficacy in patients with relapsed/refractory mantle cell lymphoma (MCL), according to findings from the phase 2 TARMAC trial (NCT04234061) published in Blood. Published March 29, 2024 |
|
|
CAR T CD19 Plus Acalabrutinib
|
CD19 CAR T Cells Plus Acalabrutinib Shows Early Activity in Relapsed/Refractory MCL CD19 CAR T cells paired with acalabrutinib (Calquence) was found to be well tolerated and to elicit responses in patients with relapsed/refractory mantle cell lymphoma. Published January 29, 2024 |
|
|
Mosunetuzumab Plus Polatuzumab Vedotin
|
Promising Response Rates with Mosunetuzumab Plus Polatuzumab Vedotin in MCL Patients with relapsed or refractory MCL who were previously treated with BTK inhibitor therapy achieved high rates of complete response (CR) when treated with a doublet regimen of fixed-duration subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (M-Pola), according to an ongoing phase Ib/II trial. Published November 21, 2023 |
|
|
Bendamustine/Obinutuzumab |
Bendamustine/Obinutuzumab Induction Generates Responses and MRD Negativity in Treatment-Naive MCL Induction therapy achieved higher complete response rates than historical bendamustine plus rituximab data in mantle cell lymphoma. Published November 18, 2024x |
|
|
Zilovertamab and Ibrutinib
|
Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma MCL, CLL, or MZL The combination is very promising in patients with R/R MCL compared with historical results for Ibrutinib alone. |
|
|
Ibrutinib and Umbralisib
|
CLL and MCL Survival Benefit from Umbralisib Plus Ibrutinib Holds Up in 4-Year Follow-Up Published online July 8, 2020 |
|
|
Ibrutinib and Venetoclax |
Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival and achieved an overall remission rate in 82% of patients with relapsed/refractory MCL according to researchers at MD Anderson Cancer Center. Published December 11, 2023 |
|
|
Ibrutinib and Venetoclax |
ASH 2023: Mantle Cell Lymphoma Updates In this 3-minute video, Matthew Matasar, MD discusses the results of the Sympatico trial in MCL and what it means for relapsed patients. Published online December 14, 2023 |
|
|
Lenalidomide and Rituximab |
Lenalidomide/Rituximab Induces Durable Responses in Mantle Cell Lymphoma in 9-Year Follow-Up The combination of lenalidomide and rituximab led to a median progression-free survival of 9 years—with 17 ongoing responses—among patients with mantle cell lymphoma. Published November 27, 2023 |
|
|
Graft -versus- Host Disease: |
||
|
Graft-versus-Host Disease FDA Approval |
FDA approves axatilimab-csfr for chronic graft-versus-host disease On August 14, 2024, the Food and Drug Administration approved axatilimab-csfr (Niktimvo, Incyte Corporation), a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy. |
|
|
Graft-versus-Host Disease |
Graft-versus-host disease (GVHD) is a complication that often occurs after a transplant using cells from a donor. This free booklet covers: · The symptoms of GVHD · The organs it can affect · Treatment options · Steps you can take to minimize the impact of GVHD on your daily life. |
|
|
Graft-versus-Host Disease |
Why 2022 Was a Banner Year for GVHD For the first time ever, transplant doctors had three different drugs at their disposal to treat it. Two of these drugs the U.S. Food and Drug Administration (FDA) had approved in 2021. Learn more about why patients with chronic GVHD have more reason for optimism than ever before. Published March 10, 2023 |
|
|
Stem Cell Transplantation: |
||
|
Stem Cell Transplants |
Blood and Marrow Stem Cell Transplantation This 72-page PDF booklet extensively covers the many issues associated with ASCT. Updated April 2023 |
|
|
Stem Cell Transplants |
Celebrating My Second Re-Birthday: 15 Lessons Learned on Surviving and Thriving after a Bone Marrow Transplant Nancy Dana underwent a stem cell transplant after being diagnosed with MCL. In this video, she shares 15 helpful lessons she learned about preparing for a transplant, making the hospital stay as comfortable as possible, and strategies for recovering and approaching life after transplant. Recorded May 22, 2024 |
|
|
Stem Cell Transplants |
BMTInfoNet Caring Connections Program Connecting patients with people who have had transplants. |
|
|
Stem Cell Transplants |
Lack of Benefit of Autologous Hematopoietic Cell Transplantation in MCL Patients in First Complete Remission with Undetectable Minimal Residual DiseaseIn this interim analysis, in the era of highly effective induction and maintenance regimens, MCL pts in first CR with uMRD6 did not benefit from consolidative auto-HCT. Pts who remain MRD+ after induction may benefit from auto-HCT. Longer follow-up will be important to confirm these findings. |
|
|
ASCT Induction and Maintnance options- Obinutuzumab VS Rituximab
|
Obinutuzumab May Control MCL Better Than RituximabThe use of obinutuzumab rather than rituximab for induction prior to and maintenance after transplantation among patients with newly diagnosed MCL resulted in improved disease control, according to the results of a study published in the journal Blood. The researchers also observed longer survival with obinutuzumab compared with rituximab.Published August 8, 2024 |
|
|
ASCT vs CAR-T |
Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma in the Era of Cell Therapy?MCL specialists discuss the value of ASCT, the current standard of care, to the newer CAR-T option and what subtypes would benefit most from each.Published October 13, 2022 |
|
|
Radiation: |
||
|
Radiation |
Radiation treatment for blood cancers This article details the four special therapy types of radiation used during blood cancer treatment. Published April 21, 2022 |
|
|
PRadiation |
Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma. Published July 9, 2019 |
|
|
Testing: |
||
|
Biomarkers |
Biomarker Testing for Cancer Treatment This fact sheet provides information about biomarker testing, which offers a way to look for genes, proteins, and other substances that can provide information about cancer. |
|
|
Minimal Residual Disease (MRD) |
Mission to Complete Remission: Utilizing MRD Testing in Blood Cancer In this podcast episode, Dr. Adriana Rossi of Mt. Sinai Hospital in New York talks about how MRD testing is being utilized for blood cancer patients and how MRD testing is guiding treatment decisions, predicting relapse and prognosis. |
|
|
Minimal Residual Disease (MRD) |
|
LLS pamphlet on MRD A two- page document which explains MRD and related testing techniques.
LLS video explaining MRD |
|
Genomics Testing |
The Revolution of Genomics: How Testing Leads to Individualized Treatment In this podcast you will learn about the crucial collaboration between pathologists and oncologists to make sure patients are getting the most accurate diagnosis and best possible treatments for their blood cancers. November 27, 2023 |
|
|
Molecular Profiling |
LLS Information Booklet An overview of molecular profiling technologies, which include immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), next-generation sequencing (NGS) and quantitative polymerase chain reaction (qPCR). |
|
|
Tumor Lysis Syndrome: |
||
|
Tumor Lysis Syndrome (TLS)
|
Evaluating Risk Factors and Treatment for Tumor Lysis Syndrome Javier Pinilla-Ibarz, MD, Moffit Center, discusses risk factors and treatment options for tumor lysis syndrome. |
|
|
Upcoming Ideas in Mantle Cell Lymphoma: NHL Cancer Diagnosis and Treatments
|
||
|
Topic: |
Article:
|
Link: |
|
CAR-E |
Genetic Engineering & Biotech News
|
CAR-T Meets CAR-E, an Enhancer Platform to Prevent Cancer Relapse Scientists at Dana-Farber have developed what they call the CAR-E therapeutic platform. The “E” in CAR-E stands for “Enhancer.” With this platform, a target antigen is fused with a low-affinity enhancer molecule to enable the precise targeting of the CAR-T molecule. The platform also facilitates the preferential delivery of immune-modulating agents post-infusion. Published July 30, 2024 |
|
BTK Degrader NX-2127
|
|
A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies This trial consisted of 5 MCL patients and is actively enrolling. NX-2127 is administered orally once daily in 28-day cycles. Published November 28, 2023 |
|
Omidubicel
|
|
FDA Approves Omidubicel for Blood Cancers in Need of Transplant Omidubicel showed encouraging clinical benefit in a phase 3 study vs standard myeloablative umbilical cord blood in patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant. Now, the FDA has approved the agent for this indication. Published April 17, 2023 |
|
AT101 |
|
First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine. Published online December 9, 2023 |
|
CB-010 |
|
CB-010 Yields Promising Data in R/R B-Cell Non-Hodgkin Lymphoma Treatment with CB-010, an allogeneic anti-CD19 CAR T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma was generally well-tolerated with a safety profile consistent with autologous or allogeneic anti-CD19 CAR-T cell therapies. Published July 17, 2023 |
|
LP-284 |
|
FDA Grants Orphan Drug Designation to Investigational Drug for Mantle Cell Lymphoma The agent produced anti-tumor activity in MCL. LP-284 shrunk and delayed progression in MCL xenograft tumors that had developed resistance following pretreatment with ibrutinib and bortezomib. Published January 16, 2023 |
|
LP-284 |
|
LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair. DDR is an intricate and sophisticated system where different types of DNA damage is repaired through different routes. Understanding the specific DNA damage and the genes involved in the corresponding repair pathway would help pinpoint targeted NHL patient populations. Published June 12, 2023 |
|
LV20.19 |
|
Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL Improved responses and favorable toxicity profiles were seen with the use of a lentiviral bispecific CAR T-cell therapy targeting both CD19 and CD20 B-cell antigens (LV20.19 CAR) in patients with mantle cell lymphoma, indicating that dual-targeting strategies could maximize patient benefit with CAR T-cell therapy in this space, according to Nirav N. Shah, MD. Published March 15, 2023 |
|
CAR-T |
Technologynetworks.com/biopharma
|
Blood Tests Could Predict Poor CAR T-Cell Therapy Outcomes Two common and easily measured blood tests can identify in advance which patients are at high risk for poor outcomes after treatment with CD19-targeted CAR T cells. Published February 6, 2024 |
|
CAR-T |
Mediacl University of South Carolina
|
CAR-T-cell therapy without side effects? Hollings researchers show results in preclinical models Graduate student Megan Tennant and Richard O'Neil, Ph.D., have promising preclinical results of a new way to administer CAR-T-cell therapy that could mean fewer side effects and the possibility of treating more disease types. Published September 7, 2023 |
|
CAR-Ts VS CAR-NKs
|
Scrip PharmaIintelligence.informa.com
|
The Cancer Cell Therapy Showdown: CAR-Ts Versus CAR-NKs Will CAR-NK cell therapies overshadow traditional CAR-T options for the treatment of some cancers? While preliminary data for CAR-NKs point to enhanced safety and solid tumor penetration, oncologists and executives discuss the pros and cons of these two approaches to cell therapy. Published March 8, 2023 |
|
CRISPR |
|
CRISPR-Based Anti-CD19 CAR T-Cell Therapy Is Safe and Effective in Relapsed/Refractory NHL The CRISPR-based nonviral PD-1 locus-specific integrated CD19-directed CAR T-cell therapy BRL-201 was associated with a manageable safety profile and elicited early indications of efficacy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Published January 9. 2024 |
|
CRISPR |
|
Testing CRISPR-Edited CAR T Cell Therapy in Lymphoma Clinical Trial CRISPR allows researchers to precisely target and modify specific genes within the T cell genome, which makes the CAR T cells work better. Published March 8, 2023 |
|
Epitope editing |
Science Translational Medicine
|
Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy By targeting a pan-hematologic antigen, a single therapeutic could be used to treat almost all hematologic malignancies, thereby accelerating clinical development. Published August 31, 2023 |
|
Ga-PentixaFor Imaging |
MedicalXpress: Society of Nuclear Medicine
|
Novel PET agent effectively detects multiple cancers, identifies patients for targeted therapies. A new molecular imaging radiotracer can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies. Published November 17, 2022 |
|
FOXO1 |
The Journal of Clinical Investigation
|
Discovery Suggests New Way to Target Mantle Cell Lymphoma A research team at Weill Cornell discovered that inhibiting the protein FOXO1 is a targetable vulnerability of mantle cell lymphoma, potentially leading to new treatments. Published October 25, 2022 |
|
Zilovertamab +Ibrutinib |
Cancernetwork.com January 6, 2022
|
Study Design Confirmed for Phase 3 Trial of Zilovertamab/Ibrutinib in Mantle Cell Lymphoma A first-in-class, humanized monoclonal antibody, zilovertamab achieves high-affinity binding with to an epitope on ROR1 that is expressed on the plasma membrane of different cancer cells. |
|
BTK Resistance |
Targeted Oncology March 25, 2021
|
Addition of Obinutuzumab and Venetoclax to Ibrutinib Overcomes Resistance in R/R MCL, Shows Activity in Newly Diagnosed MCL In relapsed and untreated patients, the combination of obinutuzumab, ibrutinib, and venetoclax achieved molecular response rates and was found to be well tolerated, results from the phase 1/2 OAsIs trial demonstrate. |
|
SOX11 |
|
SOX11 Inhibitors Demonstrate Early Activity in MCL Models Published June 24, 2021 |
|
TG-1701 |
|
Patients With CLL and Other B-Cell Malignancies Benefitted from TG-1701 Published June 5, 2021 |
|
Vaccine |
Journal of Experimental Medicine June 19, 2020
|
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial Published June 19, 2020 |
|
MCL Patient Care Information
|
||
|
Topic
|
Link |
Description |
|
3D Model Anatomical Library |
Interactive 3D models help to visualize the lymph node system, node aspiration, bone marrow biopsies, blood cell development, imaging tests, and more. |
|
|
BTK Inhibitor Side Effects |
BTK inhibitors come with a wide range of potential side effects. This article discusses ways to manage them.Published October 2023 |
|
|
Caregivers |
Caregiving can be an extremely rewarding experience, but it can also be physically and emotionally draining. This article provides some excellent tips for taking care of yourself. |
|
|
Caregivers |
Caregiving Over Coffee: Giving Yourself GraceThis video discusses the important role of caregivers and emphasizes their need to take care of themselves.Recorded November 28, 2023 |
|
|
Drug Information |
Detailed information on prescription drugs, herbs, and supplements. |
|
|
Drug Interactions |
Simply enter the names of two or more drugs and The Drug Interaction Checker will check for contraindications. |
|
|
Drug Interactions and Citrus |
Undesirable effects of citrus juice on the pharmacokinetics of drugs with a focus on recent studies. |
|
|
Drug Interactions and Grapefruit |
Mixing grapefruit with some medicines can cause serious health problems. If you take prescription medicines, ask your doctor whether it's OK to eat grapefruit or other citrus products while taking the medicines. |
|
|
Blood Clots and Deep Vein Thrombosis (DVT)
|
Two-page information sheet about blood clots and deep vein thrombosis (DVT) with information on prevention, treatment, and emergency complications. |
|
|
Exercise |
Exercise and Cancer: Celebration That You CANExercise and Cancer: Celebration That You CANExercise and Cancer: Celebration That You CANExercise and Cancer: Celebration That You CanExercise, or simply moving the body, can be an important part of cancer recovery, both physically and emotionally. In this episode, Dr. Shernan Holtan of Roswell Park and blood cancer survivors, Paul Rothweiler and Joe Grey, share about a clinical trial they developed to introduce a personalized strength training program to patients and caregivers. |
|
|
Fatigue |
Living Well after Treatment: Coping with FatigueMany patients experience significant fatigue for months or years after a stem cell transplant or CAR T-cell therapy. Learn a variety of strategies you can try to manage chronic fatigue and lessen its impact on your daily activities.Recorded April 28, 2024 |
|
|
Fatigue |
Fighting Fatigue: Ways to Save Energy and Build Back EnduranceLearn about strategies to conserve energy; adaptive equipment that can help with energy conservation; and improving stamina and strength through exercises that patients can perform at home.Recorded April 28, 2024 |
|
|
Fatigue |
Cancer-Related FatigueThis fact sheet addresses some common questions that people may have about cancer-related fatigue. |
|
|
Insomnia |
Insomnia is a common problem after a stem cell transplant. Traditional treatments, such as medications, can have side effects and are often ineffective long-term. An audio recording presented by Eric Zhou PhD, Division of Sleep Medicine, Dana-Farber Cancer Institute. |
|
|
Lab and Imaging Tests |
This LLS video series aims to answer many questions patients have about lab and imaging tests. |
|
|
Immunoglobulin |
Normal Immunoglobulin Levels by Age: Understanding Immunoglobulin |
|
|
IVIG |
An overview of the clinical uses of intravenous immunoglobulin with a brief discussion regarding its use in hematology. |
|
|
IVIG |
More information and resources on IVIG by UpToDate.com |
|
|
Medical Dictionary |
Search medical term definitions online. |
|
|
Medical calculators |
|
An assortment of medical calculators. |
|
MIPI calculator |
This MCL prognostic index (MIPI) score calculator stratifies patients into low, intermediate, and high-risk groups based on independent prognostic factors. |
|
|
Neuropathy |
Managing Peripheral Neuropathy after Transplant: A Prerecorded workshop presented by Sasha Knowlton, MD, Massachusetts General Hospital |
|
|
Neutropenic Diet |
Neutropenic Diet Information from Memorial Sloan Kettering on the diet, food preparation, storage, and recipes. |
|
|
Neutropenic Diet |
This video from Patient Power features Julie Lanford, an oncology-certified dietitian; she shares the four keys to food preparation and safety for cancer patients on a neutropenic diet |
|
|
Nutrition |
Nutrition: What You Eat Does Matter This presentation explains how to manage some common eating difficulties experienced by stem cell transplant recipients. It also discusses the impact of transplant and diet on long-term health problems such as metabolic syndrome and osteoporosis, and common myths about the relationship between cancer and certain foods and diets. |
|
|
Nutrition |
LLS Free Nutrition Consultation
LLS Nutrition and Cancer En Espanol
|
LLS Nutrition Series Patients and caregivers may receive free one-on-one phone and email consultations with an oncology dietitian. A Spanish Language video is also available. |
|
Nutrition |
Nutrition guidance during and post-treatment. |
|
|
Nutrition |
Nutrition and Physical Activity During and After Cancer Treatment: Answers to Common Questions. |
|
|
Open Notes |
After an office visit, doctors, nurses and other health care providers write notes that summarize important information about you. These notes can help you manage your healthcare. |
|
|
Pets |
Joys and Challenges of Pets in Your Home When You Have Cancer- a webcast from CancerCare. |
|
|
Port maintenance |
How to care for an Implanted Venous Access Port. |
|
|
Side Effects |
Managing Side Effects Jeffrey Zonder, MD of Karmanos Cancer Institute in Detroit, MI discusses the side effects that blood cancer patients may experience during and after treatment. |
|
|
Stress |
Managing Stress: How stress affects you and ways to cope Information about how stress affects you and tips for stress management.
|
|
|
Survivorship |
Navigating Life During and After a Blood Cancer Diagnosis Use the Survivorship Workbook to collect all the important information you need throughout diagnosis, treatment, follow-up care and long-term management of a blood cancer. |
|
|
Abbreviations and Terms Used on the MCL Mailing List
|
||
|
Listings of Abbreviations:
|
||
|
FDA.gov |
||
|
Hemeonc.org |
Listing of MCL Chemotherapies and their abbreviations |
|
|
LymphomaInfo.net
|
||
|
Burkitts.org |
Common Cancer Acronyms from Burkitt’s Lymphoma Resources |
|
|
ClinicalTrials.gov
|
||
|
Abbreviations: |
Definitions: |
Information: |
|
CBC |
Complete Blood Count |
Search for the lab test of interest Labtestsonline.org |
|
CI |
Confidence Interval |
In study results, the confidence interval represents the accuracy or precision of an estimate. |
|
CR |
Complete Response |
The disappearance of all signs of cancer in response to treatment. This does not always mean the cancer has been cured. |
|
CRS |
Cytokine Release Syndrome |
CRS is an acute systemic inflammatory syndrome characterized by fever and multiple organ dysfunction that is associated with chimeric antigen receptor (CAR)-T cell therapy, therapeutic antibodies, and haploidentical allogeneic transplantation. |
|
DoR |
Duration of Response |
Duration of response (DoR) is the length of time that a tumor continues to respond to treatment without the cancer growing or spreading. Cancer drugs that demonstrate improved DoR can produce a durable, meaningful delay in disease progression. |
|
PR |
Partial Response |
Partial response (PR) implies that further treatment will probably be required to attempt a cure. In some slow-growing tumors (including low-grade lymphomas) no further treatment may be immediately necessary until the disease starts increasing in size again. |
|
ORR |
Overall response rate
|
Overall response rate (ORR) is the proportion of patients in a trial whose tumor is destroyed or significantly reduced by a drug. ORR is generally defined as the sum of complete responses (CRs) and partial responses (PRs). Improved ORR offers tangible proof that the drug is working. |
|
OS |
Overall Survival |
Overall survival (OS) measures how long patients, who undergo a certain treatment regimen, live compared to patients who are in a control group. If a clinical trial demonstrates improved OS, it provides evidence of the drug’s value. OS is a strong and precise endpoint, as it requires having more patients and longer follow-ups compared to other clinical trial endpoints. OS is often considered the “gold standard” for measuring the clinical benefits of a cancer drug. |
|
PFS |
Progression-free survival
|
The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. |
|
BR, RB, B+R, R+B, B-R, R-B
|
Rituximab plus Bendamustine: various combination therapy |
Alternative treatment to R-CHOP see this article |
|
R-CHOP |
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone |
A regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone, with rituximab (R-CHOP) (or without-CHOP) is the standard first-line treatment for aggressive non-Hodgkin lymphoma.
|
|
R2 |
Lenalidomide (Revlimid) and rituximab |
A combination therapy of the oral drug Revlimid with Rituxan infusions.
|
|
W&W |
Watch and Wait |
Purposeful delay of the initial treatment – see this article
|
|
BMT |
Bone Marrow Transplant |
A lay discussion on types of stem cell transplants – see this article Overview of the three different types of stem cell transplants-
|
|
Allo SCT |
Allogeneic Transplant |
Allogeneic stem cell transplantation-LLS
|
|
Auto SCT |
Autologous Stem Cell Transplant |
A series of videos on transplantation issues before and after treatment:
|
|
VR-CAP |
5 drug combination therapy |
|
|
GVHD |
Graft vs Host Disease |
Graft vs. Host Disease definition
|
Last updated January 11, 2025 by: ACOR MCL Listserver group